文献速递妇科

早期卵巢癌前哨淋巴结定位(MELISA)试验——迈向替代淋巴结清扫术的又一进步

Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement.
PubMed 文献 · Gynecol Oncol · 2023-11-18

MELISA 前瞻性单臂试验纳入 30 例早期上皮性卵巢癌(FIGO I–II 期)患者,评估前哨淋巴结(SLN)定位的检出率与诊断准确性。SLN 总检出率为 90%,SLN 定位灵敏度 100%、假阴性率 0%。作者认为 SLN 定位是替代系统淋巴结清扫以降低相关并发症的潜在选择,但需进一步研究评估其对肿瘤结局的影响和成本效益。

要点

  • SLN 总检出率为 90%(27/30),初次手术与再分期手术检出率分别为 89% 和 92%。
  • SLN 定位灵敏度 100%,假阴性率 0%,超分期报告宏转移 1 例、微转移 1 例、孤立肿瘤细胞 5 例。
  • 作者认为 SLN 定位是替代系统淋巴结清扫的潜在选择,但需进一步研究评估肿瘤结局与成本效益。

核心结论

  • SLN 定位检出率高(90%),是检测早期上皮性卵巢癌淋巴结受累的准确技术。
  • SLN 定位是替代系统淋巴结清扫以降低相关并发症的潜在选择,但需进一步研究评估其对肿瘤结局的影响和成本效益。

研究设计与样本

  • MELISA 为前瞻性单臂研究,纳入经初次手术或再分期手术确诊的早期上皮性卵巢癌(FIGO I 和 II 期)患者,共 30 例。
  • SLN 定位方法为向骨盆漏斗韧带和子宫卵巢韧带注射 0.2 mL 37-mBq 99mTc-纳米胶体白蛋白和 2 mL 2.5 mg/mL 吲哚菁绿,切除 SLN 后行完整系统盆腔和腹主动脉旁淋巴结清扫,SLN 采用超分期分析。
  • 主要结局为使用一种或两种示踪剂的总 SLN 检出率;次要结局为检测淋巴结转移的诊断准确性及可能影响 SLN 检出的因素。

主要发现

  • 30 例患者中 27 例(90%)检出 SLN;初次手术和再分期手术的检出率分别为 89% 和 92%。
  • 27 例中 26 例观察到腹主动脉旁引流为优势淋巴播散途径。
  • 超分期病理报告列出 1 枚 SLN 宏转移、1 枚微转移和 5 枚孤立肿瘤细胞;SLN 定位灵敏度为 100%,假阴性率为 0%。
  • 单因素分析显示,未检出 SLN 的患者中子宫肌瘤、子宫腺肌病和子宫内膜异位症的比例较高(分别为 100%、67%、67%),但差异无统计学意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究评估 SLN 定位对肿瘤结局的影响及其成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sistematic pelvic and para-aortic lymphadenectomy is part of the staging surgery for early-stage epithelial ovarian cancer, with no therapeutic value. The Mapping Sentinel Lymph Nodes In Early-Stage Ovarian Cancer (MELISA) trial prospectively assessed the SLN detection rate and the diagnostic accuracy of the SLN mapping technique in patients with early-stage epithelial ovarian cancer. METHODS: This prospective, single-arm study included patients diagnosed with early-stage epithelial ovarian cancer (FIGO stages I and II), via either primary surgery or re-staging surgery. SLN mapping was performed by injecting 0.2 mL of 37-mBq 99mTc-nanocoloid albumin and 2 mL of 2.5 mg/mL indocyanine green into the infundibulopelvic and utero-ovarian ligaments. After removal of SLNs, a complete systematic pelvic and para-aortic lymphadenectomy was performed. SLN Ultrastaging analysis was applied. The primary outcome was the overall SLN detection rate, either with one or both tracers. Secondary outcomes were the diagnostic accuracy of detecting lymph node metastases and factors that may influence SLN detection. RESULTS: Thirty patients were included. SLNs were identified in 27 patients (90%). Detection rates in primary and re-staging surgery were 89% and 92%, respectively. Para-aortic drainage was the predominant lymphatic spread, observed in 26 of 27 patients. Ultrastaging pathologic reports listed 1 SLN with macrometastasis, 1 with micrometastasis, and 5 with isolated tumor cells; the sensitivity of SLN mapping was 100%, with a false-negative rate of 0%. Univariate analysis showed a nonsignificant higher proportion of patients with uterine fibroids, adenomyosis, and endometriosis (100%, 67%, 67%, respectively) in patients in whom SLNs were not detected. CONCLUSION: SLN mapping has a high detection rate (90%) and is an accurate technique for detecting lymph node involvement in early-stage epithelial ovarian cancer. SLN mapping is a potential alternative to systematic lymphadenectomy to reduce associated morbidity, but further research is needed to evaluate the impact of SLN mapping on oncologic outcomes and its cost-effectiveness.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Agustí N, Vidal-Sicart S, Paredes P, et al. Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement. Gynecol Oncol. 2023. PMID: 37980769. doi:10.1016/j.ygyno.2023.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。